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Context: Teriparatide and denosumab are effective treatments for osteoporosis and typically 
reserved as second-line options after patients have used bisphosphonates. However, limited 
head-to-head comparative effectiveness data exist between teriparatide and denosumab.  
Objective: We compared changes in bone mineral density (BMD) between groups treated with 
teriparatide or denosumab after using bisphosphonates, focusing on the change in BMD while on 
either drug over 2 years.  
Design: Observational cohort study using electronic medical records from two academic medical 
centers in the US.  
Participants: The study population included osteoporotic patients > 45 years who received 
bisphosphonates over one year prior to switching to teriparatide or denosumab.  
Outcome Measures: Annualized BMD change from baseline at the lumbar spine, total hip and 
femoral neck.  
Results: Patients treated with teriparatide (n=110) were compared to those treated with 
denosumab (n=105); the mean (SD) age was 70 (10) years and median duration (IQR) of 
AD
VA
N
CE
 A
RT
IC
LE
:
TH
E 
JO
UR
NA
L 
O
F 
CL
IN
IC
AL
 
EN
D
O
CR
IN
O
LO
G
Y 
& 
M
ET
AB
O
LI
SM
JC
EM
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/advance-article-abstract/doi/10.1210/jc.2019-00924/5526755 by U
niversity of Liverpool user on 07 August 2019
AD
VA
NC
E 
AR
TI
CL
E
The Journal of Clinical Endocrinology & Metabolism; Copyright 2019  DOI: 10.1210/jc.2019-00924 
 
 
2
bisphosphonate use was 7.0 (5.6-9.7) years. Compared to denosumab users, teriparatide users 
had higher annualized BMD change at the spine by 1.3% (95% CI 0.02, 2.7%), but lower at the 
total hip by -2.2% (95% CI -2.9 to -1.5%) and the femoral neck by -1.1% (95% CI -2.1 to -
0.1%). Those who switched to teriparatide had a transient loss of hip BMD for the first year, with 
no overall increase in the total hip BMD over two years. 
Conclusions: Among patients who use long-term bisphosphonates, the decision of switching to 
teriparatide should be made with caution, especially for patients at high risk of hip fracture.  
This is a head-to-head comparison study using 14 years electronic medical records. We compared 
teriparatide versus denosumab on BMD in patients switching from long-term bisphosphonate. 
INTRODUCTION 
Therapeutic options for osteoporosis have increased over the past two decades (1). 
Bisphosphonates are the most widely used anti-osteoporosis agents in clinical practice (2–4). The 
anabolic agent teriparatide (human parathyroid hormone 1-34) and the antiresorptive agent 
denosumab (monoclonal antibody to receptor activator of nuclear factor kappa-Β ligand) are 
potent drugs often reserved as second-line treatments for patients who lose bone mineral density 
(BMD) or fracture while on a bisphosphonate, or who have severe disease(1).  
In randomized controlled trials (RCT) of bisphosphonate-naïve patients, the estimated 
fracture risk reduction using denosumab was 68% for vertebral fractures and up to 20% for 
nonvertebral fractures at 12 months, compared with placebo (5). In similar trials, teriparatide 
reduced vertebral fractures by 65% and nonvertebral fractures by 63% compared with placebo 
over a median follow-up of 21 months(6). However, there is some evidence that prior anti-
resorptive therapy – in particular bisphosphonates – may influence the effects of both 
teriparatide(7–12) and denosumab(13). Over 63% of teriparatide users(14) and 54% of 
denosumab(15) users in the US had been prescribed a prior anti-osteoporosis agent, mostly 
bisphosphonates. Thus, the therapeutic effect of teriparatide and denosumab in typical clinical 
practice may not be the same as reported in clinical trials. 
There is only one head-to-head RCT comparing denosumab and teriparatide that included 
participants who switched from long-term bisphosphonates, but almost two-thirds of patients in 
this trial were bisphosphonate-naïve(16). This head-to-head trial showed that denosumab and 
teriparatide improved BMD similarly at the lumbar spine, total hip and femoral neck over 24 
months. An indirect meta-analysis that included mostly bisphosphonate-naïve patients showed 
that teriparatide increased BMD 2.6% more than denosumab at the spine, but 1.3% less than 
denosumab at the total hip over 24 months(17). These data conflict regarding the optimal 
medication if further treatment is needed after bisphosphonate use.  
We used real-world data to compare the effectiveness of switching to teriparatide versus 
denosumab on BMD in patients with prior long-term bisphosphonate-use. 
METHODS 
Study design 
In a group of patients who had used bisphosphonates for over 12 months, we compared changes 
in BMD between those switching to teriparatide or denosumab. The primary outcomes were the 
differences in annualized BMD change from baseline between two agents at the lumbar spine, 
total hip and femoral neck for 2 years.  
Study population and data sources 
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Partners HeathCare electronic medical record (EMR) is used by several hospitals, including 
Brigham and Women’s Hospital and Massachusetts General Hospital. These hospitals provide 
care for approximately 4.6 million patients in and around Boston, Massachusetts. We used the 
medical records of patients who took osteoporosis medications from Jan 2004 to Dec 2017. 
Potentially eligible patients were over 45 years of age and had used at least 12 months of 
prior bisphosphonate, including alendronate, ibandronate, risedronate, pamidronate or zoledronic 
acid. They were required to have subsequently used teriparatide or denosumab for more than 6 
months, and undergone at least two dual-energy X-ray absorptiometry (DXA) scans as detailed 
below. From this group of potentially eligible patients, the following exclusion criteria were 
applied: a history of Paget’s disease, simultaneous use of denosumab, teriparatide and/or 
bisphosphonates, high-dosage denosumab (120 mg/ month) (prescribed for cancer patients), and 
a prior course of teriparatide. The Partners HealthCare Institutional Review Board approved all 
aspects of this study. 
Exposure and outcome assessment 
The exposure of interest was treatment with teriparatide or denosumab after at least 12 months of 
bisphosphonate use. First, we identified all patients who had a least one prescription of 
teriparatide or denosumab through an automated search of the EMR, then drug usage details 
(duration and dosage) were verified by one author (HL) through chart review. For each patient, 
the dose, duration and reason for discontinuation were documented based on the chart review. 
The date of the first dose of denosumab or teriparatide was defined as the index date. We 
classified drug brand or generic names into four categories: oral bisphosphonates (alendronate 10 
mg once daily or 70 mg once weekly, ibandronate 150 mg once monthly, risedronate 35 mg once 
weekly, 75 mg on two consecutive days every months or 150 mg once monthly), intravenous 
bisphosphonate (zoledronic acid 5 mg once yearly or 2.5 mg every 6 months, ibandronate 3 mg 
every 3 months, pamidronate 60 mg every 6 months or 30 mg every 3 months), denosumab (60 
mg subcutaneous every 6 months) and teriparatide (20 µg subcutaneous daily) for each patient.  
We extracted BMD (g/cm2) from routine DXA scans (QDR 4500/4500A; Hologic, Bedford, 
MA) of the posteroanterior lumbar spine, total hip, and femoral neck. The baseline DXA test 
window was defined as 2 years before through 3 months after the index date. Follow-up of 
teriparatide and denosumab use was truncated at 27 months to achieve similar drug exposure 
durations for both treatment groups. Thus, the follow-up DXA test window was defined as 6 to 
27 months after the index date so as to include all qualified DXA tests in this window. For 
patients with multiple DXA tests within the baseline or follow-up window, the DXA closest to 
the index date or last date of drug use were chosen. All interim DXA tests between baseline and 
last DXA were included for analysis(18).  
Covariate assessment 
Patient characteristics were collected from the EMR. Variables of interest included age, sex, 
race, body mass index (BMI), other medications related to bone mineral density (hormone 
replacement therapy, raloxifene, glucocorticoids) and comorbidities included in the Charlson 
comorbidity index(19). Comorbidities were defined using corresponding International 
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) or ICD-10-CM 
codes before the index date. We also collected information on prior fragility fractures(20) 
defined as those occurring in the year prior to the index date. Prior bisphosphonate treatment 
(duration and washout period) was verified by chart review. Duration of prior bisphosphonate 
use was defined as the combined duration of all bisphosphonates (alendronate, ibandronate, 
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risedronate, pamidronate or zoledronic acid). The washout period was defined as the interval 
between bisphosphonate cessation and initiation of denosumab or teriparatide. 
Statistical analyses 
Baseline characteristics were compared between the two groups using descriptive statistics. 
There were imbalances between the two groups in baseline characteristics, thus we used 
matching weights - an extension of inverse probability of treatment weighting method - to 
improve balance across the two treatment groups(21,22). We first fit a propensity score logistic 
model in which the treatment group (teriparatide or denosumab) was the dependent variable and 
all potential confounders (age, sex, race, BMI, prior oral bisphosphonate duration, prior 
intravenous bisphosphonate duration, prior bisphosphonate washout period, baseline BMD, prior 
fragility fracture, glucocorticoids history, HRT history, raloxifene history, hyperthyroidism, any 
malignancy, renal disease, rheumatoid arthritis, osteoarthritis, esophageal disease, diabetes, 
anemia, hypertension, hyperlipidemia, congestive heart disease, peripheral cardiovascular 
disease, stroke, COPD, hemiplegia or paraplegia and Charlson comorbidity index) were 
independent variables. The predicted probability from this model represents each patient’s 
probability of receiving teriparatide. These probabilities were used to assign each patient a 
weight, such that the weighted teriparatide group and weighted denosumab group were balanced 
in their baseline characteristics(23), similar to a 1:1 propensity score-matched cohort. In contrast 
to propensity score matching, the weighting method retains all patients, thereby maximizing the 
use of all available data(21,22). 
We then used weighted generalized estimating equations (GEE) to compare BMD change in 
the treatment groups. Change in BMD from baseline to follow-up was modeled as a linear term 
to provide annualized change estimates. The models included interaction terms between the 
treatment group and the time variable; their coefficients are interpreted as the difference in 
annualized change between the two treatments. To aid interpretability and comparability with 
prior clinical trials(5,6,24–26), we calculated the percentage change in BMD from baseline. To 
explore non-linear BMD changes, we performed the same analysis with time categorized into 
baseline (-24 to 3 months), 12 months (9 to 15 months) and 24 months (21 to 27 months). Since 
consolidation with anti-resorptive agents are typically recommended after 2 years of teriparatide, 
we also estimated BMD response through the consolidation stage, thus assessing denosumab 
over 4 years and teriparatide for 2 years plus 2 further years of consolidation.  
We performed a series of sensitivity analyses to test the robustness of the primary analysis. 
First, we conducted a 1:1 propensity score-matched analysis using greedy matching within a 
caliper of 0.1 standard deviations of the propensity score to provide estimates for a subgroup 
matched for baseline characteristics. Second, since percentage change from baseline might be 
vulnerable to extreme values, we repeated the same analysis with actual BMD (g/cm2) and 
converted resulting differences to percentage change from the mean baseline BMD (27). Third, 
we repeated the above analyses excluding patients who had baseline DXA >12 months before the 
index date to improve the accuracy of baseline BMD. Fourth, we excluded patients with very 
low BMD (the lowest 10%) to further improve comparability between the two groups. Fifth, 
patients who did not complete two years of treatment were excluded. Sixth, patients in the 
teriparatide group with index date before June 6, 2010 were excluded, as denosumab was not on 
the market before this date. Last, we excluded rare cases of patients who had >10 years of prior 
bisphosphonate use. All analyses were performed using R-3.4.3 (https://cran.r-project.org). 
RESULTS 
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Among 778 patients with at least one prescription of denosumab or teriparatide, 215 patients 
were eligible for the current analysis (Figure 1). Patients were 94% female with a mean (SD) 
age of 70 (10) years. The median duration (interquartile range [IQR]) of prior bisphosphonate 
use was 7.0 (5.6-9.7) years.  
The baseline characteristics of the two exposure groups are shown in Table 1. Most baseline 
characteristics were quite similar between the two groups. The teriparatide group had lower 
BMD at all three anatomic sites (the lumbar spine, total hip and femoral neck), shorter duration 
of prior bisphosphonate and lower prevalence of prior fractures than denosumab group. After 
applying propensity score-based weighting, baseline characteristics were well balanced across 
both exposure groups(28). Potential confounders such as age, BMI, hyperthyroidism, esophageal 
disease, prior fragility fracture, any malignancy, hemiplegia/paraplegia, rheumatoid arthritis, 
osteoarthritis, baseline BMD (the lumbar spine, total hip, and femoral neck) and prior 
bisphosphonate treatment duration, were all balanced between the two exposure groups (Table 
1). In the 1:1 propensity score-matched subset, the above mentioned potential confounders were 
also adequately balanced(29). 
Differences in BMD change between teriparatide and denosumab 
In the weighted analyses, denosumab significantly increased BMD at all three anatomic sites (the 
lumbar spine, total hip and femoral neck), while teriparatide only significantly increased BMD at 
the lumbar spine (Table 2). Over 2 years, compared to denosumab, teriparatide users had greater 
annualized BMD increase at the spine by 1.3% (95% CI 0.02 to 2.7%, p=0.046), but also greater 
annualized BMD loss at the total hip by -2.2% (95% CI -2.9 to -1.5%, p <0.001) and femoral 
neck by -1.1% (95% CI -2.1 to -0.1%, p=0.029).  
Non-linear BMD change trajectories for teriparatide and denosumab are shown in Figure 2. 
Teriparatide and denosumab demonstrated different changes in BMD; patients who switched to 
teriparatide showed a non-significant trend for greater increases in lumbar spine BMD than 
denosumab through the first 2 years. However, teriparatide users had BMD loss at the hip (both 
total hip and femoral neck) in the first year, with no overall change over 2 years. During the 
consolidation stage, teriparatide users had continued BMD response at lumbar spine through 36 
and 48 months, but responses at the hip areas were lower compared to values observed at the 
lumbar spine(30). 
Sensitivity analyses 
Effect size estimates from sensitivity analyses were consistent with the primary analysis (Figure 
3). Since most sensitivity analyses only included a subset of the original study population, 
especially for the 1:1 propensity score-matched analysis, they were less efficient and had wider 
confidence intervals than the primary analysis. For lumbar spine BMD, differences between the 
two treatments ranged from 0.7 to 2.4%. For the total hip, teriparatide had lower annualized 
BMD increase than denosumab, with estimated differences ranging from -1.7 to -2.7%. At the 
femoral neck, teriparatide again had lower annualized BMD increases than denosumab, with the 
estimated difference ranging from -0.2 to -1.4%. 
DISCUSSION 
In this observational study of long-term bisphosphonates users, annualized BMD increase after 
switching to teriparatide was 1.3% higher at the lumbar spine, and lower by 2.2% at the total hip 
and 1.1% at the femoral neck, compared to switching to denosumab. Those who switched to 
teriparatide had a transient loss of hip BMD for the first year, with no overall increase in total hip 
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BMD over two years. In patients with long-term bisphosphonate-use, our results suggest that 
clinical decisions to switch to teriparatide should be made with caution, especially for patients at 
high risk of hip fracture. 
In our study, the 2.2% annual difference in total hip BMD between teriparatide and 
denosumab groups and 1.1% at the femoral neck may suggest a clinically meaningful difference 
in fracture risk reduction. BMD change is regarded as the most important surrogate for 
evaluating therapeutic response. A recent meta-analysis of 21 randomized trials showed that 
changes in hip BMD over two years explained 60-65% of the treatment-related reduction in 
fracture risk(31), although only some of the data are from patients with prior bisphosphonates 
use. More specifically, a 3% increase in hip BMD at 1 year was associated with a 46% reduction 
in nonvertebral fracture risk(32).  
The efficacy of teriparatide and denosumab are different between bisphosphonate-naïve 
patients and long-term bisphosphonates users. Previous results of randomized clinical trials 
found that teriparatide increased total hip BMD by 2.6%(6) and denosumab 3.6% at 12 months 
in treatment-naïve patients(26). However, in long-term bisphosphonate treated patients, the 
effect sizes were much smaller, total hip BMD increase at 12 months after switching to 
teriparatide was -0.9% and denosumab 2.0% (Figure 2).  
The hip BMD response using teriparatide in prior bisphosphonates users was less than 
expected. There are possible mechanistic reasons for these findings. With long-term 
bisphosphonate-use, bone turnover is inhibited, and cortical bone is highly mineralized. At 
cortical sites such as the hip, teriparatide induces absorption of old bone matrix and apposition of 
new bone matrix, not yet fully mineralized(8,33,34). A transient fall in BMD can be seen at the 
beginning of teriparatide therapy due to the resorption of highly mineralized old bone and 
subsequently increased cortical porosity (8,35,36). BMD then slowly increases with ongoing 
treatment as new bone fully mineralizes. In our patients who had a median duration of prior 
bisphosphonate-use of 7 years, BMD gained by new bone mineralization may be offset by old 
bone resorption for at least the first year. In contrast, denosumab binds and inhibits receptor 
activator of nuclear factor-κB ligand to achieve extensive suppression of bone turnover and 
increases BMD at all skeletal sites(37). Switching to denosumab increases BMD even after long-
term anti-resorptive therapy (38). Transition to denosumab from alendronate produced greater in 
BMD at all measured anatomic sites and a further reduction in biochemical markers of bone 
turnover(38).  
The poor hip BMD response in patients switching from bisphosphonates to teriparatide 
highlights the importance of drug sequence when using anabolic and anti-resorptive 
agents(7,9,16,39–41). Cosman et al. summarized BMD changes at the hip in various published 
clinical trials investigating the effects of teriparatide when used after an antiresorptive agent(7). 
BMD at the hip fell below baseline values for the first 12 months after switching, resulting a 
decrease of -2.7 to -0.3% in total hip BMD, but returned to baseline at 18 months (-1.7 to 0.9% ) 
and almost increased above baseline by 24 months (-0.7 to 2.9%)(8–10,42,43). Our study 
showed similar BMD trajectories: hip BMD dropped for the first 12 months and then returned to 
the baseline level. Since switching to teriparatide in prior bisphosphonate-treated patients does 
not achieve optimal BMD gain at all sites, and teriparatide can only be used for 24 months, this 
routinely used strategy needs examination. 
To maximize the treatment effect, substantial data suggest using teriparatide before 
bisphosphonates (44–46). In one study, teriparatide followed by bisphosphonates had better 
BMD gains than bisphosphonates followed by teriparatide(47). Over a period of 19 to 24 
AD
VA
N
CE
 A
RT
IC
LE
:
TH
E 
JO
UR
NA
L 
O
F 
CL
IN
IC
AL
 
EN
D
O
CR
IN
O
LO
G
Y 
& 
M
ET
AB
O
LI
SM
JC
EM
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/advance-article-abstract/doi/10.1210/jc.2019-00924/5526755 by U
niversity of Liverpool user on 07 August 2019
AD
VA
NC
E 
AR
TI
CL
E
The Journal of Clinical Endocrinology & Metabolism; Copyright 2019  DOI: 10.1210/jc.2019-00924 
 
 
7
months, teriparatide achieved an average gain of approximately 3% in the hip area (total hip and 
femoral neck). After teriparatide, the transition to a bisphosphonate led to 2% additional increase 
in the hip area after 1 year(46). We evaluated prescription patterns in our study population and 
observed that teriparatide followed by bisphosphonates was rarely used. The most widely used 
pattern in the last decade at Partners HealthCare was bisphosphonates followed by teriparatide. 
We examined the BMD increase profile of this pattern and did not identify a relative gain in 
BMD during the 2-year treatment compared with teriparatide followed with anti-resorptive 
agents in a prior study(46). Thus, in patients who are likely to require more than one drug, 
previous sequential studies(8–10,42,46,48) and our results suggest initial use of teriparatide 
followed by an antiresorptive as an alternative choice to achieve maximal gains in BMD(41).  
The main strength of this study is that we used 14 years of observational data to emulate a 
randomized trial comparing the effectiveness of denosumab vs. teriparatide when an RCT is not 
available. While theoretically possible, it is unlikely that an RCT will ever be conducted for this 
question. Thus, results of the current study provide an important piece of information for clinical 
decision-making. This study not only showed a transient decrease for teriparatide in the hip areas 
but also provided a contrast with denosumab, suggesting switching to teriparatide should be 
made with caution, especially for patients at high risk of hip fracture. We applied several 
rigorous methods to reduce bias and confounding in both study design and data analysis. First, 
we used an active-comparator and new-user design to help mitigate confounding by design and 
facilitate confounding adjustment by establishing correct temporality between pretreatment 
variables and drug exposure(49,50). Second, we balanced the baseline characteristics between 
two groups using matching weights, an extension of inverse probability of treatment weighting 
method, and estimated BMD increase with marginal structural models.  
Despite these rigorous methods, our study still has limitations. First, unlike a randomized 
controlled trial, which can balance both the measured and unmeasured confounders, head-to-
head comparison with observational data can only balance the measured confounders using 
statistical approaches, there is possibility for unmeasured confounding that could create bias. For 
example, concomitant use of proton pump inhibitors would reduce BMD; if patients who 
switched to teriparatide were more likely to use proton pump inhibitors, then this would be an 
unmeasured confounder. However, compared to the effect of bisphosphonate, glucocorticoids 
and HRT, the effect of such proton pump inhibitors might be minor. Second, this was a 
retrospective study using routine clinical data; therefore not all patients in the source population 
underwent sufficient numbers of DXA tests to describe BMD changes, leading to the exclusion 
of over half study population during the selection process. Current guidelines(1,51) recommend 
the same DXA monitoring schedule (1 or 2 years after initiating osteoporosis drugs) for patients 
who switched to denosumab or teriparatide. Thus the risk of selection bias is low. Sensitivity 
analysis using patients who had baseline DXA >12 months before switching produced similar 
results. Third, our primary analysis assumed that patients who switched to denosumab or 
teriparatide were from the same population, despite teriparatide (2001) and denosumab (2010) 
having different marketing dates. An additional sensitivity analysis restricted to switching after 
June 2010 reached the same conclusions. Fourth, the various bisphosphonates used in the period 
before switching to teriparatide or denosumab have an inherent difference in efficacy, and our 
study did not have enough power to study the interaction between response and prior 
bisphosphonate type. Last, we did not evaluate the difference in fracture events due to low 
fracture incidence in the study cohorts. As the evidence on BMD change and fracture risk 
reduction are based on data using anti-resorptive agents, further studies using fracture endpoints 
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are needed to confirm the efficacy difference between teriparatide and denosumab in patients 
treated with prior bisphosphonates.  
CONCLUSION 
Among long-term bisphosphonate users that switched to a different class of osteoporosis 
treatment, denosumab and teriparatide both increased BMD at the spine, but BMD increases at 
the total hip and femoral neck were greater in the denosumab group. Switching to teriparatide led 
to a transient BMD loss at the hip for the first year, but whether this loss affects fracture risk is 
unknown. In this particular population, our results suggest the decision of switching to 
teriparatide should be made with caution, especially for patients at high risk of hip fracture. 
Future trials or large observational studies comparing fracture end-points with special focus on 
the first 2 years after switching are needed to support our findings. 
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Figure 1. Flow chart showing the cohort selection process. 
Figure 2 BMD change trajectories of switching to denosumab versus teriparatide in patients with 
prior bisphosphonate-use. Teriparatide and denosumab demonstrated different changes in BMD; 
patients who switched to teriparatide showed a non-significant trend for greater increases in 
lumbar spine BMD than denosumab through the first 2 years. However, teriparatide users had 
BMD loss at the hip (both total hip and femoral neck) in the first year, with no overall change 
over 2 years. Time categorized into baseline (-24 to 3 months), 12 months (9 to 15 months) and 
24 months (21 to 27 months). 
Figure 3 Sensitivity analyses for the BMD increase differences between denosumab and 
teriparatide. Effect size estimates from sensitivity analyses were consistent with the primary 
analysis at all the three sites (the lumbar spine, total hip, and femoral neck). 
Table 1 Baseline characteristics of study cohorts before and after weighting 
Variables Unweighted cohort Weighted cohort DMAb TPTD SMD DMAb TPTD SMD 
N 105 110  - -  
AD
VA
N
CE
 A
RT
IC
LE
:
TH
E 
JO
UR
NA
L 
O
F 
CL
IN
IC
AL
 
EN
D
O
CR
IN
O
LO
G
Y 
& 
M
ET
AB
O
LI
SM
JC
EM
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/advance-article-abstract/doi/10.1210/jc.2019-00924/5526755 by U
niversity of Liverpool user on 07 August 2019
AD
VA
NC
E 
AR
TI
CL
E
The Journal of Clinical Endocrinology & Metabolism; Copyright 2019  DOI: 10.1210/jc.2019-00924 
 
 
13 
Age (mean) 70.2 70.3 0.014 67.9 66.8 0.018 
Male (%) 7.6   4.5 0.129 5.4 5.8 0.015 
Race (White, %) 93.3 91.8 0.058 90.2 90.3 0.003 
BMI (mean) 24.1 22.8 0.287 23.2 23.9 0.049 
Smoking history (%) 23.8 10.9 0.346 12.2 12.0 0.010 
Obesity (%) 18.1   8.2 0.297 9.6 11.9 0.082 
Hyperthyroidism (%) 12.4 12.7 0.010 13.1 13.8 0.020 
Esophagus disease (%) 54.3 41.8 0.252 42.3 42.2 0.002 
Any malignancy (%) 36.2 11.8 0.595 16.8 17.0 0.005 
Renal disease (%) 29.5   9.1 0.536 10.6 11.4 0.024 
Diabetes (%) 24.8 14.5 0.259 17.0 16.6 0.012 
Hypertension (%) 64.8 57.3 0.154 57.6 57.0 0.012 
Hyperlipidemia (%) 78.1 69.1 0.205 70.8 72.4 0.034 
Cerebrovascular disease (%) 18.1 19.1 0.026 11.3 9.7 0.053 
Chronic pulmonary disease (%) 36.2 37.3 0.022 37.7 38.0 0.006 
Anemia (%) 48.6 37.3 0.230 43.9 45.3 0.028 
Hemiplegia or paraplegia (%) 21.9 14.5 0.192 13.7 14.2 0.015 
Rheumatoid arthritis (%) 11.4 13.6 0.067 5.9 5.5 0.014 
Osteoarthritis (%) 65.7 59.1 0.137 59.2 57.4 0.036 
Charlson comorbidity index (mean) 3.8 2.1 0.554 2.4 2.6 0.013 
Fractures       
    Fragility fracture (%) 36.2 50.9 0.300 39.4 36.3 0.063 
BMD       
    Lumbar spine (T-score) -2.3 -2.7 0.396 -2.4 -2.3 0.061 
    Total hip (T-score) -1.9 -2.3 0.467 -2.0 -1.9 0.046 
    Femoral neck (T-score) -2.3 -2.5 0.372 -2.3 -2.2 0.057 
    Lumbar spine (g/cm2) 0.79 0.74 0.402 0.77 0.78 0.059 
    Total hip (g/cm2) 0.71 0.66 0.474 0.70 0.71 0.042 
    Femoral neck (g/cm2) 0.60 0.57 0.384 0.60 0.61 0.054 
Osteoporosis agents       
    Prior oral BP duration (years) 5.9 6.8 0.199 6.6 6.7 0.008 
    Prior intravenous BP duration (years) 1.4 0.8 0.271 1.1 1.2 0.045 
    Glucocorticoids (%) 60.0 55.5 0.092 57.0 54.0 0.067 
    HRT (%) 36.2 46.4 0.208 44.7 41.9 0.057 
    Raloxifene (%) 9.5 13.6 0.129 11.9 11.3 0.016 
BP washout period (month) 24.4 9.7 0.607 14.6 15.7 0.043 
DMAb, denosumab; TPTD, teriparatide; SMD, standardized mean difference; BMI, body mass index; BMD, bone 
mineral density; BP, bisphosphonates; HRT, hormone replacement therapy; 
Table 2 Difference in annualized percentage BMD change between denosumab and  teriparatide 
over 2 years 
Site Therapy Mean annualized BMD changes from baseline % (95% CI) 
Difference between teriparatide and 
denosumab % (95% CI) P value 
Lumbar spine Denosumab 3.1 (2.3, 3.9) Reference  Teriparatide 4.4 (3.4, 5.5) 1.3 (0.02, 2.7) 0.046 
Total Hip Denosumab 1.9 (1.5, 2.4) Reference  Teriparatide -0.3 (-0.8, 0.3) -2.2 (-2.9, -1.5) <0.001 
Femoral neck 
Denosumab 1.8 (1.2, 2.4) Reference  
Teriparatide 0.7 (-0.2, 1.5) -1.1 (-2.1, -0.1) 0.029 
Weighted generalized estimating equations (GEE) were used to compare BMD change in the weighted cohorts. 
Change in BMD from baseline to follow-up was modeled as a linear term to provide annualized change estimate. 
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